The Cleveland-based regenerative medicine company that is preparing for commercialization of its MultiStem cell therapy named Daniel A. Camardo as CEO, effective Feb. 14. He also will join the company's board of directors. William (B.J.) Lehmann, who has been interim CEO at Athersys for nearly a year, will return to the roles of president and chief operating officer, which he held prior to the interim appointment.
Athersys and HEALIOS K K Announce Advancement of Their MultiStem Commercial Partnership pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Athersys Announces CEO Transition
CLEVELAND, Ohio (BUSINESS WIRE) Feb 16, 2021
Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem ® cell therapy, today announced that Dr. Gil Van Bokkelen has stepped down as Chairman and Chief Executive Officer, effective immediately. The Athersys Board has appointed William (B.J.) Lehmann, the Company’s President and Chief Operating Officer, as Interim Chief Executive Officer. Dr. Ismail Kola, Lead Director of the Athersys Board, has been appointed Chairman of the Board.
The Company’s Board is commencing a comprehensive search process to identify a permanent CEO. The Board intends to identify and select a CEO who can guide Athersys in the commercial stage.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Athersys Announces Cooperation Agreement With HEALIOS K.K.
February 16, 2021 GMT
CLEVELAND (BUSINESS WIRE) Feb 16, 2021
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem ® cell therapy, today announced that it has entered into a cooperation agreement with HEALIOS K.K. (“Healios”), the Company’s largest shareholder and one of its commercial partners, and Dr. Hardy TS Kagimoto, a member of the Company’s Board and the Chairman and Chief Executive Officer of Healios. The cooperation agreement is intended to reaffirm the mutual commitment to collaborative development of MultiStem in Japan.
The Cleveland-based developer of the MultiStem cell therapy announced Tuesday morning, Feb. 16, that Van Bokkelen has stepped down from the roles effective immediately. Van Bokkelen co-founded Athersys in 1995. Athersys said its board of directors has appointed William (B.J.) Lehmann, the company's president and chief operating officer, as interim CEO. The board 'intends to identify and select a CEO who can guide Athersys in the commercial stage,' the company said.